Stockreport

ARS Pharmaceuticals Inc (SPRY) Q3 2024 Earnings Call Highlights: Strong Cash Position and NEPHI ... [Yahoo! Finance]

ARS Pharmaceuticals, Inc.  (SPRY) 
PDF Total Operating Expenses: $23.8 million in Q3 2024. SG&A Expenses: $19.3 million, expected to increase in Q4 2024. GAAP Net Loss: $19.1 million or $0.20 per share i [Read more]